Novo Nordisk says concizumab showed favorable safety profile in Phase 2 studies
Concizumab demonstrated a favorable safety profile and clinical proof of concept for the prevention of bleeding episodes in patients with haemophilia A and haemophilia A/B with inhibitors, Novo Nordisk announced. Results from the main phase of 24 weeks of the two phase 2 trials were presented at the 27th International Society on Thrombosis and Haemostasis Congress. A manuscript describing results of the trials has been submitted to the journal "Blood," the company noted. "We are delighted that the results from the concizumab phase 2 trials support its use as a safe and well-tolerated subcutaneously administered prophylactic therapy in all patients with haemophilia, regardless of inhibitor status, and we are excited to proceed with phase 3," said Ludovic Helfgott, executive vice president of Novo Nordisk Biopharm Operations. The global phase 3 programs will be initiated later this year, the company said.